{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:51:01Z","timestamp":1783486261935,"version":"3.55.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ijbiomac.2023.125867","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T15:33:44Z","timestamp":1689694424000},"page":"125867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK\/ERK and PI3K\/AKT pathways"],"prefix":"10.1016","volume":"248","author":[{"given":"Hui","family":"Dang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjun","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiju","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ijbiomac.2023.125867_bb0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J. Clin."},{"issue":"18","key":"10.1016\/j.ijbiomac.2023.125867_bb0010","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.295.18.2164","article-title":"Increasing incidence of thyroid cancer in the United States, 1973-2002","volume":"295","author":"Davies","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ijbiomac.2023.125867_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f4706","article-title":"Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours","volume":"347","author":"Brito","year":"2013","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.125867_bb0020","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/thy.1999.9.421","article-title":"An overview of the management of papillary and follicular thyroid carcinoma","volume":"9","author":"Mazzaferri","year":"1999","journal-title":"Thyroid"},{"issue":"11","key":"10.1016\/j.ijbiomac.2023.125867_bb0025","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nrc.2017.79","article-title":"New perspectives for targeting RAF kinase in human cancer","volume":"17","author":"Karoulia","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.ijbiomac.2023.125867_bb0030","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1073\/pnas.0711741105","article-title":"Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity","volume":"105","author":"Tsai","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.ijbiomac.2023.125867_bb0035","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.125867_bb0040","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/2159-8290.CD-12-0531","article-title":"Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas","volume":"3","author":"Montero-Conde","year":"2013","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.125867_bb0045","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrm2868","article-title":"MicroRNA control of signal transduction","volume":"11","author":"Inui","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"10.1016\/j.ijbiomac.2023.125867_bb0050","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrd3179","article-title":"Targeting microRNAs in cancer: rationale, strategies and challenges","volume":"9","author":"Garzon","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijbiomac.2023.125867_bb0055","article-title":"The role of MicroRNAs in human cancer","volume":"1","author":"Peng","year":"2016","journal-title":"Signal Transduct Tar"},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.125867_bb0060","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ijc.28399","article-title":"Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells","volume":"134","author":"Yu","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"17","key":"10.1016\/j.ijbiomac.2023.125867_bb0065","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.4161\/cc.7.17.6597","article-title":"Mechanisms of microRNA deregulation in human cancer","volume":"7","author":"Deng","year":"2008","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.125867_bb0070","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1261\/rna.7233305","article-title":"Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs","volume":"11","author":"Yi","year":"2005","journal-title":"RNA"},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.125867_bb0075","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccell.2016.10.001","article-title":"ERK activation globally downregulates miRNAs through phosphorylating Exportin-5","volume":"30","author":"Sun","year":"2016","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.125867_bb0080","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/hep.29819","article-title":"Targeting Pin1 by inhibitor API-1 regulates microRNA biogenesis and suppresses hepatocellular carcinoma development","volume":"68","author":"Pu","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ijbiomac.2023.125867_bb0085","doi-asserted-by":"crossref","first-page":"E962","DOI":"10.1210\/jc.2013-3147","article-title":"PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-deazaneplanocin a","volume":"99","author":"Cui","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.ijbiomac.2023.125867_bb0090","doi-asserted-by":"crossref","first-page":"E1163","DOI":"10.1210\/jc.2013-3729","article-title":"ZIC1 is a putative tumor suppressor in thyroid cancer by modulating major signaling pathways and transcription factor FOXO3a","volume":"99","author":"Qiang","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125867_bb0095","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1186\/s13046-021-02195-z","article-title":"ZIP10 is a negative determinant for anti-tumor effect of mannose in thyroid cancer by activating phosphate mannose isomerase","volume":"40","author":"Ma","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.ijbiomac.2023.125867_bb0100","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1038\/s41418-021-00762-7","article-title":"The noncoding RNAs SNORD50A and SNORD50B-mediated TRIM21-GMPS interaction promotes the growth of p53 wild-type breast cancers by degrading p53","volume":"28","author":"Su","year":"2021","journal-title":"Cell Death Differ."},{"issue":"15","key":"10.1016\/j.ijbiomac.2023.125867_bb0105","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.7150\/thno.35219","article-title":"Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK\/ERK and PI3K\/AKT pathways via distinct mechanisms","volume":"9","author":"Su","year":"2019","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.125867_bb0110","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s12020-022-03202-9","article-title":"Sorafenib decreases glycemia by impairing hepatic glucose metabolism","volume":"78","author":"Ma","year":"2022","journal-title":"Endocrine"},{"issue":"10","key":"10.1016\/j.ijbiomac.2023.125867_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.201807736","article-title":"Self-assembly of therapeutic peptide into stimuli-responsive clustered Nanohybrids for Cancer-targeted therapy","volume":"29","author":"He","year":"2019","journal-title":"Adv. Funct. Mater."},{"issue":"9","key":"10.1016\/j.ijbiomac.2023.125867_bb0120","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41418-018-0065-z","article-title":"Pin1 impairs microRNA biogenesis by mediating conformation change of XPO5 in hepatocellular carcinoma","volume":"25","author":"Li","year":"2018","journal-title":"Cell Death Differ."},{"issue":"6892","key":"10.1016\/j.ijbiomac.2023.125867_bb0125","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"35","key":"10.1016\/j.ijbiomac.2023.125867_bb0130","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1200\/JCO.2008.18.0786","article-title":"Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer","volume":"26","author":"Di Nicolantonio","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"9871","key":"10.1016\/j.ijbiomac.2023.125867_bb0135","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0140-6736(13)60109-9","article-title":"Progress in molecular-based management of differentiated thyroid cancer","volume":"381","author":"Xing","year":"2013","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ijbiomac.2023.125867_bb0140","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.125867_bb0145","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1078-0432.CCR-11-2246","article-title":"Predictive and prognostic roles of BRAF mutation in stage III Colon Cancer: results from intergroup trial CALGB 89803","volume":"18","author":"Ogino","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125867_bb0150","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1200\/JCO.2014.56.8253","article-title":"Association between BRAF V600E mutation and recurrence of papillary thyroid cancer","volume":"33","author":"Xing","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.ijbiomac.2023.125867_bb0155","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ijbiomac.2023.125867_bb0160","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41416-019-0526-2","article-title":"Exploring the best treatment options for BRAF-mutant metastatic colon cancer","volume":"121","author":"Taieb","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.ijbiomac.2023.125867_bb0165","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1210\/er.2019-00007","article-title":"Targeted therapy for advanced thyroid Cancer: kinase inhibitors and beyond","volume":"40","author":"Cabanillas","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ijbiomac.2023.125867_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.123367","article-title":"Snake venom, a potential treatment for melanoma. A systematic review","volume":"231","author":"Bialves","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"issue":"9839","key":"10.1016\/j.ijbiomac.2023.125867_bb0175","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.125867_bb0180","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7387","key":"10.1016\/j.ijbiomac.2023.125867_bb0185","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2023.125867_bb0190","doi-asserted-by":"crossref","DOI":"10.1177\/1758835921992974","article-title":"BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer","volume":"13","author":"Ros","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"10.1016\/j.ijbiomac.2023.125867_bb0195","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","article-title":"Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial","volume":"17","author":"Brose","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125867_bb0200","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/thy.2014.0123","article-title":"BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer","volume":"25","author":"Falchook","year":"2015","journal-title":"Thyroid"},{"issue":"11","key":"10.1016\/j.ijbiomac.2023.125867_bb0205","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrc1997","article-title":"MicroRNA signatures in human cancers","volume":"6","author":"Calin","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.125867_bb0210","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrc1840","article-title":"Oncomirs - microRNAs with a role in cancer","volume":"6","author":"Esquela-Kerscher","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"7043","key":"10.1016\/j.ijbiomac.2023.125867_bb0215","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature03677","article-title":"C-Myc-regulated microRNAs modulate E2F1 expression","volume":"435","author":"O\u2019Donnell","year":"2005","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ijbiomac.2023.125867_bb0220","doi-asserted-by":"crossref","first-page":"1888-+","DOI":"10.1016\/j.cell.2022.04.030","article-title":"A plant immune protein enables broad antitumor response by rescuing microRNA deficiency","volume":"185","author":"Qi","year":"2022","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.125867_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/biom11050639","article-title":"Improving gemcitabine sensitivity in pancreatic Cancer cells by restoring miRNA-217 levels","volume":"11","author":"Panebianco","year":"2021","journal-title":"Biomolecules"},{"issue":"16","key":"10.1016\/j.ijbiomac.2023.125867_bb0230","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.7150\/thno.34588","article-title":"MicroRNA biogenesis is enhanced by liposome-encapsulated Pin1 inhibitor in hepatocellular carcinoma","volume":"9","author":"Sun","year":"2019","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.125867_bb0235","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41419-022-04550-0","article-title":"Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib","volume":"13","author":"Hu","year":"2022","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125867_bb0240","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13046-021-01831-y","article-title":"Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK\/ERK signal by PLX4032","volume":"40","author":"Su","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.ijbiomac.2023.125867_bb0245","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.ejca.2010.04.006","article-title":"The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene","volume":"46","author":"Kelleher","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125867_bb0250","first-page":"13","article-title":"Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer (review)","volume":"45","author":"Wang","year":"2021","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.125867_bb0255","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3892\/mco.2021.2373","article-title":"Analysis of ALK, IDH1, IDH2 and MMP8 somatic mutations in differentiated thyroid cancers","volume":"15","author":"Murugan","year":"2021","journal-title":"Mol Clin Oncol"},{"issue":"13","key":"10.1016\/j.ijbiomac.2023.125867_bb0260","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1158\/0008-5472.CAN-10-4041","article-title":"Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene","volume":"71","author":"Murugan","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2023.125867_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2019.10.022","article-title":"Special issue: PI3K\/Akt signaling in human cancer","volume":"59","author":"Murugan","year":"2019","journal-title":"Semin. Cancer Biol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2023.125867_bb0270","article-title":"Clinical implications of mTOR expression in papillary thyroid Cancer-A","volume":"15","author":"Derwich","year":"2023","journal-title":"Systematic Review, Cancers (Basel)"},{"issue":"26","key":"10.1016\/j.ijbiomac.2023.125867_bb0275","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1038\/s41388-019-0787-5","article-title":"Identification and characterization of two novel oncogenic mTOR mutations","volume":"38","author":"Murugan","year":"2019","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.ijbiomac.2023.125867_bb0280","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/14728222.2011.594044","article-title":"The mTOR protein as a target in thyroid cancer","volume":"15","author":"Souza","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"issue":"9","key":"10.1016\/j.ijbiomac.2023.125867_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/genes10090709","article-title":"Molecular alterations in thyroid Cancer: from bench to clinical practice","volume":"10","author":"Tirro","year":"2019","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ijbiomac.2023.125867_bb0290","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.semcancer.2019.07.003","article-title":"mTOR: role in cancer, metastasis and drug resistance","volume":"59","author":"Murugan","year":"2019","journal-title":"Semin. Cancer Biol."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813023027629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813023027629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T17:10:15Z","timestamp":1726938615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813023027629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":58,"alternative-id":["S0141813023027629"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.125867","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK\/ERK and PI3K\/AKT pathways","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.125867","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"125867"}}